Epoetin Alfa Articles

Bi-monthly Procrit effective in CKD anemia

27 November 2006

Shire launches Ph IIIb Dynepo trial

6 November 2006

Study: Procrit cheaper than rival anemia drugs

6 November 2006

Stock Commentary - New York week to Oct 16, 2006

23 October 2006

Split patent decison for Amgen and Shire

14 August 2006

Amgen's 2nd-qtr 2006 sales up 14% to $3.6B

31 July 2006

J&J's record 2nd-qtr 2006 sales boost profit 10%

24 July 2006

US counterfeit drug market growing, and costing pharma industry billions

24 July 2006

ITC judge rules peg-EPO covered by exemption

17 July 2006

ITC accepts Amgen's complaint against Roche over Peg-EPO

15 May 2006

Ortho Biotech's Procrit: "current labeling best"

1 May 2006

Amgen sees $1B profits in 1st-qtr 2006

24 April 2006

Stock Commentary - New York week to Feb 6

13 February 2006

Amgen starts $1B Puerto Rico site expansion

13 February 2006

Amgen's fourth-qtr income up 29%, and full year 2005 earnings per share rise 33%

6 February 2006

US FDA issues revised safety warning on Epogen, Aranesp and Procrit

12 December 2005

FDA licenses to Amgen production facilities

12 September 2005

Study recommends new regimen for J&J's Procrit

22 August 2005

Amgen sees whopping 38% net profit and 26% sales rises, beating all expectations

1 August 2005

Generic threats to erythropoeitin, as key process patents expire

9 May 2005

Amgen posts 26% EPS hike, raises forecast

25 April 2005

Japan stock market week to January 24

31 January 2005

J&J's 4th-qtr net earnings plunge 34%

31 January 2005

Amgen adds safety warning to Aranesp

24 January 2005

Biogenerics to command more than $12B by 2010

17 January 2005

Is greater commercialization of research just a pipe-dream? - by David Tubby of Marks & Clerk

15 November 2004

Japan's Chugai posts nine-month results in line with forecasts

8 November 2004

Amgen sees 3rd-qtr earnings climb 21% but profit drops; lifts outlook for 2004

25 October 2004

US biotech sector tumbles in July as investors react to choppy market conditions

23 August 2004

J&J outperforms 2nd-qtr expectations despite Procrit and Cypher stent woes

19 July 2004

European vs US biotechnology - 2003 reviewed by Ernst & Young

24 May 2004

Amgen unveils a promising R&D pipeline but investors remain uncertain

5 April 2004

TKT regains European rights to Dynepo

5 April 2004

FDA to view Aranesp and Procrit in May

29 March 2004

Global Rx sales up 9% in 2003, with US market rising 11%, reports IMS

29 March 2004

US Rx drug sales up 11.5% in 2003, growth sustained by new products, says IMS

23 February 2004

Tokyo pharma stocks - week to Jan 26

2 February 2004

Strong sales boost Amgen profit

2 February 2004

J&J 4th-qtr EPS up 35%, sales rise 20%

26 January 2004

US health, safety and drug access: FDA views 2003's actions and its plans for 2004

26 January 2004

Amgen forecasts 18%-30% rise in 2004 profits, boosted by lead drugs

22 December 2003

US Medicare bill and biotech reimbursement

15 December 2003

Stock Commentary - New York

8 December 2003

US market developments in 2002-3 and the rise of generics; CBI meeting

8 December 2003

J&J raises forecast on strong 3rd quarter

20 October 2003

Improving the treatment of anemia in cancer, discussed at ECCO

20 October 2003

Biotech steadies itself for re-opening of IPO window; strong 4th qtr expected

15 September 2003

J&J recalls batches of Eprex

18 August 2003

Stock Commentary - New York

28 July 2003

Acquisition charges hit J&J 2nd-qtr results

21 July 2003

US FDA's most serious enforcement activities "having unprecedented success"

7 July 2003

FDA tells J&J, GSK and Allergan to pull misleading ads

30 June 2003

Stock Commentary - New York

16 June 2003

Stock Commentary - New York

28 April 2003

Amgen outperforms in 1st qtr, raises forecast

28 April 2003

Profits and sales up at J&J in first quarter on higher prescription turnover

21 April 2003

2002 world pharma sales growth: slower but still healthy, says IMS

24 March 2003

J&J ordered to pay Amgen's costs in Procrit case

3 February 2003

Profits up at J&J in fourth quarter as lead drugs and devices perform well

27 January 2003

Stock Commentary week to Jan 13 - New York

20 January 2003

Amgen says appeals court confirms Epogen ruling

13 January 2003

Biotechs outperform Nasdaq, but small companies are close to failure: Burrill report

19 August 2002

J&J defends Eprex in Puerto Rico investigation

5 August 2002

10 most effective US DTC television ads

5 August 2002

Stock Commentary - New York

29 July 2002

Puerto Rican site woes cause J&J's shares to tumble 16%

29 July 2002

New use for Amgen's Aranesp OKed in USA

29 July 2002

J&J

22 July 2002

Swedish pharma continues steady growth; 26.7bn kronor sales in 2001

8 July 2002

Aranesp gets CPMP backing for two drugs

10 June 2002

Protecting pharmaceuticals from counterfeiting; a practical guide

10 June 2002

Amgen's Aranesp beats J&J's Procrit

3 June 2002

Double-digit growth rates elude most blockbuster firms, says Datmonitor

27 May 2002

Amgen first-quarter 2002 revenues top $900 million; net income rises 11.8%

6 May 2002

J&J earnings climb 18.2% in 1st qtr

22 April 2002

Biotech deals boost strong pharma M&A activity in 2001, says PwC

11 March 2002

NEJM study finds more aplasia cases with J&J's Eprex

25 February 2002

Fresenius snubs J&J in favor of Amgen

28 January 2002

J&J posts healthy increase in sales and earnings for 2001

28 January 2002

Tally of NCEs in 2001 lends credence to talk of R&D productivity

21 January 2002

Amgen planning to acquire Immunex Corp in $18 billion deal?

7 January 2002

Amgen planning to acquire Immunex Corp in $18 billion deal?

7 January 2002

Amgen confirms $16 billion bid for Immunex

7 January 2002

Amgen planning to acquire Immunex Corp in $18 billion deal?

18 December 2001

Amgen planning to acquire Immunex Corp in $18 billion deal?

14 December 2001

Stock Commentary - New York

6 December 2001

J&J adds warning to Eprex labeling

6 December 2001

US pharma's R&D cost claims "cannot be reconciled with its IRS filings,"

5 December 2001

Amgen expecting strong sales and earnings growth in 2002

22 November 2001

Amgen third-quarter earnings up 5%

29 October 2001

J&J posts healthy increase in sales and earnings for 3rd-qtr 2001

17 October 2001

Amgen files for Aranesp in cancer anemia

21 September 2001

Amgen's Aranesp gets clearance in USA for renal anemia

19 September 2001

J&J posts healthy increase in sales and earnings, excluding Alza merger

19 July 2001

Aranesp's European launch sets up tussle for EPO market with Roche's

27 June 2001

Amgen set to go head-to-head with J&J after Aranesp clearance in EU

12 June 2001

2000 US Rx sales up 14.9% to $145 billion, with volume the main driver, says

4 June 2001

Aranesp equivalent to Epogen in Ph III trial

15 May 2001

Stock Commentary - New York

3 May 2001

Tokyo pharma stocks week to April 30

2 May 2001

Showing 101-200 of 348 articles

Go to beginningPreviousNextGo to end